3Jemal A, Bray F, Center MM, Ferlay J, Ward E, For- man D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90 [PMID: 21296855 DOI: 10.3322/caac.20107].
4Takara K, Sakaeda T, Okumura K. An update on overcoming MDRl-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006; 12: 273-286 [PMID: 16454744 DOI: 10.2174/1381612067 75201965].
5Beck WT. The cell biology of multiple drug resis- tance. Biochem Pharmacol 1987; 36:2879-2887 [PMID: 2888464 DOI: 10.1016/0006-2952(87)90198-5].
6Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influ- encing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-283 [PMID: 11033070 DOI: 10.1016 / S0928-0987(00)00114-7].
7Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol 2011; 21:59-69 [PMID: 21144900 DOI: 10.1016/ j.semcancer.2010.11.002].
8Haus-Cohen M, Assaraf YG, Binyamin L, Benhar I, Reiter Y. Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single- chain Fv antibody fragment targeted to an extracel- lular epitope. Int J Cancer 2004; 109:750-758 [PMID: 14999785 DOI: 10.1002/ijc.20037].
9Goldstein LJ. Clinical reversal of drug resistance.Curr Probl Cancer 2005; 19:65-124 [PMID: 7600845 DOI: 10.1016/S0147-0272(07)80004-3].
10Kaufmann S H, Vaux DL. Alterations in the apop- totic machinery and their potential role in an ticancer drug resistance. Oncogene 2003; 22:7414-7430 [PMID: 14576849 DOI: 10.1038/sj.onc.1206945].
